About us

We believe in the 4Ds: Drugs, Devices, Diagnostics and Digital

CMS Ventures, launched in 2020, is the investment arm of China Medical System Holdings Limited (CMS), a well-established, innovation-driven specialty pharma founded in 1995, and listed on the Main Board of the Stock Exchange of Hong Kong Limited (stock code: 867). CMS Ventures receives support from AstraZeneca and Cambridge Judge Business School.

CMS is recognising the vibrancy and the vitality of the UK biotech and life sciences ecosystem, through financing CMS Ventures, based in Cambridge (UK), to invest (off balance sheet) up to £25m in biotech and life sciences start-ups in the UK over the next five years.

Through this new collaboration CMS, AstraZeneca and CJBS demonstrate a common objective of strengthening the pipeline of opportunities in biotech and life sciences, more specifically in the areas of therapeutics, diagnostics, devices and digital health.

CJBS, through various programmes including its work with AstraZeneca has established networks and relationships in the life science and med- tech space in Cambridge, and elsewhere in the UK.

AstraZeneca has a strong desire to support the identification of early-stage companies by evaluating, coaching, mentoring and advising these companies in order to promote the life science ecosystem in Cambridge and across the wider UK.

CMS Ventures offers its portfolio companies unparalleled access to international markets, in particular China, with a trusted partner of choice on the ground.



CMS kangzhe
University of Cambridge Judge Business School

Our Criteria

CMS Ventures provides patient capital for ambitious Biotech and Life Sciences start-ups in the 4Ds (Drugs, Devices, Diagnostics and Digital), interested in entering the Chinese market with a trusted partner of choice.

Find out more